To investigate the safety and efficacy of transcatheter arterial chemoembolization (TACE) with embospheres for the treatment of unresectable hepatocellular carcinoma (HCC).
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer-related death worldwide, and more than 80% of cases occur in Asia. 1, 2 It is estimated that 45% of HCC cases occur in China, where it kills approximately 110 000 people per year. 3 Surgery is regarded as the major curative treatment for HCC.
Unfortunately, only about 20% benefit from surgery, as most patients are diagnosed at a late stage.
A recent Cochrane meta-analysis concluded that transcatheter arterial chemoembolization (TACE) was not supported for use in patients with unresectable HCC. 4 However, other studies [5] [6] [7] [8] showed that TACE or transarterial embolization (TAE) should be favored compared with no active treatment or supportive care. Hence TACE, which has been shown to improve survival, is now widely adopted for unresectable HCC. Treatment by TACE with lipiodol and anticancer agents, followed by selective arterial embolization, will lead to a strong cytotoxic effect and ischemia with relatively less toxicity. Different agents may be used for embolization, with a mixture of iodized oil and chemotherapeutic agents followed by gelatin sponge pellets being the most popular TACE technique.
With the application of polyvinyl alcohol, trisacryl gelatin microspheres (embospheres; Merit Medical Systems, Inc., South Jordan, UT, USA) and drugeluting beads, the common iodized oil TACE technique has been challenged by one that uses microspheres for the treatment of liver tumors. 9, 10 A recent large overview analyzed three meta-analyses of TACE vs TAE; none of them found any significant difference between the two techniques. 5 However, another study found that, compared to TAE, TACE significantly prolonged progression-free survival (PFS) and time to progression (TTP), but not overall survival (OS). 11 Thus, though TAE is reported to be efficacious, the ultimate outcome with TACE is better. 12 The application of TACE using microspheres and lipiodol can maintain the advantages of each substance concurrently.
The usual sizes of embospheres are 100-700 μm. Microspheres of 100-300 μm in size can cause damage to bile ducts and liver fibrous connective tissue. Accordingly, microspheres of 300-500 μm in size are most suitable for the embolization of liver tumors. 13, 14 Therefore, the current study aimed to evaluate the safety and efficacy of TACE using lipiodol emulsion mixed with chemotherapeutic agents, followed by treatment with embospheres (300-500 μm in size), in patients with inoperable HCC.
PATIENTS AND METHODS

Patients
Patients with inoperable HCC who were treated with Embo-TACE or conventional TACE (cTACE) in Fujian Provincial Cancer Hospital (Fuzhou, Fujian Province, China) between May 2010 and March 2014 were retrospectively included in this study. The Embo-TACE group was treated with TACE using lipiodol emulsion mixed with chemotherapeutic agents, followed by embosphere treatment; while the cTACE group received conventional TACE with a conventional lipiodol emulsion mixed with chemotherapeutic agents, followed by treatment with gelatin sponge pellets. The diagnosis of HCC was based on high serum alpha-fetoprotein (AFP; ≥400 ng/mL), imaging findings (magnetic resonance imaging [MRI] or computed tomography [CT]), or needle biopsy of the liver when AFP <400 ng/mL, in accordance with the Chinese Diagnostic and Staging Standards for Primary Hepatocellular carcinoma (2001). 15 Patients with hepatitis B received anti-viral treatment. Eligibility criteria were: (i) aged 18-75 years; (ii) Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2; (iii) no indication for resection; (iv) Barcelona Clinic liver cancer staging (BCLC) stage B or C; and (v) liver function of Child-Pugh A to B. Exclusion criteria were: (i) infiltrative or diffused HCC; (ii) previous systemic anticancer therapy; (iii) fluoroscopic arteriovenous fistula and significant cardiovascular disease; (iv) pregnant or breastfeeding women.
The study was approved by the Ethics Committee of Fujian Provincial Cancer Hospital and all participants provided their written informed consent before treatment.
Treatment procedure
The general TACE procedures performed at our hospital are as follows. Patients fasted 8 h before TACE. All patients were injected with an antiemetic before the procedure. A 4-F RH catheter (Cordis Corp., Miami, FL, USA) was inserted into the femoral artery under local anesthesia. In order to identify the sizes and locations of tumor nodules, hepatic arteriography and superior mesenteric arterial portovenography were performed. The right or left hepatic artery, or segmental tumor-feeding hepatic artery, was super-selectively catheterized with a 2.6-F microcatheter (Stride; Asahi Intecc Co., Ltd., Pathumthani, Thailand). The TACE chemotherapy regimen consisted of 150 mg or 200 mg oxaliplatin and 1 000 mg floxuridine. Floxuridine (1 000 mg) was injected when the catheter was interposed into the common hepatic artery. Lipiodol embolization was subsequently performed super-selectively. The dosage of oxaliplatin was adjusted according to the patient's age (150 mg for patients >60 years and 200 mg for those <60 years). Using the pumping method, lipiodol (Laboratorie Guerbet, Aulnay-sous-Bois, France) and oxaliplatin emulsions were mixed at a ratio of 10 mL to 100 mg. Under fluoroscopic monitoring, the emulsion of lipiodol mixed with oxaliplatin was injected slowly into the tumor without retrograde flow. The amount of lipiodol emulsion given depended on the tumor size and arterial blood flow.
If possible, the remaining oxaliplatin was injected into the common hepatic artery after lipiodol embolization. At the end of the TACE procedure, the cTACE group was treated with gelatin sponge pellets (2 mm in diameter). The chemoembolization procedure of Embo-TACE group was completed with an infusion of embospheres (300-500 μm in diameter; Biosphere Medical, Paris, France) at a maximum dose of 2 mL after infusion of the anticancer agent and the oxaliplatin-lipiodol emulsion.
After embolization, an angiography was performed to determine the extent of vascular occlusion. Multiphasic CT and MRI were carried out 1 month after TACE. Two radiologists compared follow-up images with baseline images to assess the patients' responses to TACE.
The TACE procedure was repeated at least 45 days after the first session in patients with evidence of viable tumor persistence, as defined by the modified response evaluation criteria (mRECIST). 16 Subsequent TACE treatments used the same occlusion agent as the first treatment. TACE was discontinued until the presentation of symptomatic progression or the development of liver failure despite tumor progression of the target lesions or presentation of new lesions.
In the Embo-TACE group, a dose of 5-20 mL (mean dose 13.45 mL) lipiodol emulsion was injected slowly until the outline of the image of the tumor appeared under fluoroscopic monitoring and tumor staining decreased by over 50%, embospheres were then injected until complete stasis was achieved in the tumor-feeding vessels. Each vial of embospheres was diluted with 10 mL non-ionic contrast media. To avoid reflux of the microspheres, the embospheres were administered by fluoroscopically guided injections (Figs 1,2) . Patients in the cTACE group received a dose of 5-35 mL (mean dose 17.35 mL) lipiodol emulsion until tumor staining mostly disappeared, followed by treatment with gelatin sponge pellets.
Safety assessment
Toxicity was appraised and graded according to NCI CTCAE 3.0. 17 Conventional adverse reactions after TACE treatment included liver injury and postembolization syndrome, presenting as pain, fever, nausea and vomiting. Cases developed postembolization syndrome of grade ≥2 were recorded. Liver function-related parameters included serum albumin (ALB), total bilirubin (TBIL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). Liver function indices were tested 3 days pre-TACE and 7 days post-TACE, respectively. Gastrointestinal bleeding or pulmonary embolisms occurring up to one month after TACE were identified as serious TACE-related complications. Patient's quality of life (QoL) was assessed by ECOG PS. 
Efficacy assessment
The treatment response was assessed 1 month after TACE using the mRECIST. An overall response rate (ORR) was defined as the complete response (CR) plus partial response (PR). OS was defined as the time from the initiation of the first TACE treatment until death or the date of the last follow-up for patients who were alive and censored. TTP was prescribed as the time from the initiation of the first TACE treatment until the time when the disease progressed.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 (IBM, Armonk NY, USA). Continuous variables were expressed as mean AE standard error of the mean and compared between the two groups by the Student's ttest, while categorical variables were expressed numbers and percentages or frequency and compared using the χ 2 test. Liver function indices such as ALB, TBIL, AST and ALT were evaluated by paired t-tests and independent t-tests, before and after TACE, and between the two groups. Kaplan-Meier survival analysis and log-rank test were used. Univariate and multivariate Cox-regression analyses of OS were performed. The 95% confidence interval (CI) for the survival proportion was calculated, along with standard errors. P < 0.05 was considered statistically significant.
RESULTS
Clinical characteristics of patients
A total of 110 patients with inoperable HCC were included in this study, including 53 in the Embo-TACE group and 57 in the cTACE group. The median age was 53 years (range 18-74 years). All patients with an ECOG performance status grade of 0-2 received a total of 303 sessions of TACE, with a median of two sessions (range 1-9). Follow-up was continued through 1 September 2016. The median follow-up period was 12 months. Altogether five patients were lost to follow-up after 6-46 months. On the basis of the BCLC staging system, 80 patients were at stage B and 30 were at stage C. Altogether 27 patients had portal vein thrombosis. No significant differences in baseline characteristics were noted between the two groups ( Table 1) .
At the end of follow-up, 18 patients received additional percutaneous ethanol injection therapy (10 in the Embo-TACE group and eight in the cTACE group), 10 received additional radiation therapy (six in the Embo-TACE group and four in the cTACE group), one in each group received secondary surgical treatment, three received additional radiofrequency ablation therapy (one in the Embo-TACE group and two in the cTACE group), three in each group received additional chemotherapy, and 12 patients received additional sorafenib therapy (seven in the Embo-TACE group and five in the cTACE group). No significant differences in additional therapy were noted between the two groups.
TTP
The median TTP was 7.0 months (95% CI 4.3-9.7 months) in the Embo-TACE group and 5.4 months (95% CI 3.6-7.2 months) in the cTACE group. The median TTP in the Embo-TACE group was significantly longer than that of the cTACE group (P = 0.035; Fig. 3 ).
OS
At the time of the final analysis, 100 (90.9%) patients died, including 44 from the Embo-TACE group and 56 from the cTACE group. The median survival period was 15 months (95% CI 11.7-18.3 months) in the Embo-TACE group and 12 months (95% CI 10.4-13.6 months) in the cTACE group. Survival rates at 1, 2 and 3 years were 61.1%, 31.8% and 18.5% respectively, in the Embo-TACE group, and 43.1%, 19 .7% and 7.2%, respectively, in the cTACE group (P = 0.039; Fig. 4 ). Figure 3. Time to progression (TTP) survival curves of patients with unresectable hepatocellular carcinoma in the two groups. The median TTP in the Embo-TACE group is significantly longer than in the conventional transcatheter arterial chemoembolization (cTACE) group (P = 0.035). , cTACE; , Embo-TACE, TACE followed by embosphere treatment. , cTACE; , Embo-TACE, TACE followed by embosphere treatment.
Univariate and multivariate Cox regression analyses revealed that additional therapy and local responses
one month after the first TACE treatment were associated with OS. Additional therapy was associated with improved OS. The better the local responses one month after the first TACE treatment, the longer the OS (Tables 2,3) .
Response rates
Baseline evaluations were conducted within one week prior to TACE. One month after the first TACE, CT scan or MRI was performed to evaluate the ORR. Table 4 shows the rates of local responses one month after the first TACE treatment according to the mRE-CIST. In the Embo-TACE group, no patient achieved CR, 41 patients achieved PR with an ORR of 77.4%, nine had stable disease (SD) and three had progressive disease (PD). In the cTACE group, no patient achieved CR, 43 patients achieved PR with an ORR of 75.4%, eight had SD and six achieved PD. There was no significant difference in ORR between the two groups (P = 0.827; Table 4 ).
Safety
Serum ALB, TBIL, AST and ALT were evaluated 3 days before the first TACE treatment, and no significant differences were observed between the two groups. Serum ALT levels tested 7 days after the first TACE treatment were significantly higher in the cTACE group than in the Embo-TACE group (P = 0.015), while ALB, TBIL and AST levels revealed no significant differences (Table 5) .
Grade ≥ 2 post-embolization syndromes were observed in this study. The Embo-TACE group included 13 patients with grade ≥ 2 pain and six with grade ≥ 2 fever. The cTACE group included 29 patients with grade ≥ 2 pain and 16 with grade ≥ 2 fever. Pain and fever in the cTACE group were significantly more severe than in the Embo-TACE group (P = 0.006 and P = 0.033, respectively; Table 6 ).
ECOG PS was assessed 3 days before and 7 days after the first TACE treatment. ECOG PS in the Embo-TACE group improved significantly more than in the cTACE group (P = 0.000; Table 7 ). Most adverse events in this study involved postembolization syndrome and liver injury. Gastrointestinal bleeding occurred in only one patient 2 days after TACE treatment in the cTACE group. Pulmonary embolism occurred 3 days after TACE in one patient from the Embo-TACE group. For the patient with gastrointestinal bleeding, bleeding stopped with conservative treatment 14 days after TACE. The severe respiratory symptoms and imaging abnormality of the patient diagnosed with pulmonary embolism normalized. The patient was discharged from hospital after receiving conservative treatment for 20 days.
DISCUSSION
Although TACE is the standard treatment method for HCC patients at BCLC stage B, there is increasing evidence to support the view that TACE is an effective therapy for advanced HCC patients with vascular invasion or extrahepatic spread. It may provide equal or improved survival, compared with reported outcomes with sorafenib. 18, 19 Thus, some patients had portal vein tumor thrombus (PVTT) in this study, so TACE was still applied.
cTACE treatment, using lipiodol mixed with a chemotherapeutic agent, has been widely used for unresectable HCC. However, the active ingredients Values are expressed as mean (standard error of the mean). cTACE, conventional transcatheter arterial chemoembolization; Embo-TACE, TACE followed by embosphere treatment. dissipate with time and local tumor recurrence was common. Thereafter, microspheres were developed to enhance the terminal vessel blockade. The recent introduction of embospheres in China has provided a valuable alternative treatment for patients with unresectable HCC. This study assessed the safety and efficacy of TACE using embospheres for unresectable HCC. Common adverse reactions after TACE include liver injury and the post-embolization syndrome symptoms of pain, fever, nausea and vomiting. 21 The presentation of toxicity in the current study was as expected, based on liver function injury and postembolization syndrome, though encouraging safety results were also observed.
One of the main indicators of liver function, ALT level, was significantly higher in the cTACE group 7 days post-TACE. Taking into account the limitations of this study, which was the higher proportion of BCLC stage C patients in the Embo-TACE group, the increase in AST level was higher in the cTACE group 7 days post-TACE. The main indicators of post-embolization syndrome, grade ≥2 pain and grade ≥2 fever, were significantly more severe in the cTACE group. ECOG PS in the Embo-TACE group was significantly more improved than in the cTACE group.
A total of 303 TACE procedures were performed in this study. Severe TACE-related complications were observed in two patients, including one with gastrointestinal bleeding in the cTACE group and one with pulmonary embolism in the Embo-TACE group. The incidence of severe TACE-related complications is lower than that reported in a single-arm study that used bland TAE with embospheres (0.66% vs 1.89%). 21 Hence, the safety of the regime used in this study was superior to that in the former study. 21 There was no significant difference in ORR between the two groups. The limitation of this study that Embo-TACE group had a higher proportion of BCLC stage C patients might have affected the detection rate of positive results. Even so, the median TTP in the Embo-TACE group was significantly longer than that of the cTACE group (7.0 months vs 5.4 months). The median survival period in Embo-TACE group was significantly longer than that of cTACE group (15 months vs 12 months).
The mean maximum diameter of HCC lesions was >10 cm. Large primary liver cancer often requires a high dose of lipiodol during cTACE treatment, which may cause severe post-embolization syndrome. TACE regime using lipiodol emulsion with embospheres requires a lower dose of lipiodol. The innovation of TACE followed by embospheres is that this treatment procedure results in a strong cytotoxic effect combined with fewer adverse effects. It has the advantages of both a slow release of chemotherapeutic drugs and the permanent embolization of embospheres. The two groups used the same chemotherapy regimens, which are increasingly used in TACE because of their low toxicity. [22] [23] [24] [25] Univariate and multivariate Cox regression analyses showed that additional therapy and local responses 1 month after the first TACE treatment were associated with OS. In accordance with the expert consensus of non-operative therapies for combined modality treatment of HCC, 26 the additional therapy was associated with improved OS. Local responses 1 month after the first TACE treatment predict the differences in OS, which is supported by another study. 27 The results of this study indicated that TACE, using lipiodol emulsion mixed with chemotherapeutic agents and followed by embospheres, resulted in better prognoses in terms of TTP and OS compared with cTACE. Furthermore, this regimen was better tolerated. Additional therapy and local responses 1 month after the first TACE were independent prognostic factors for OS. Additional large, randomized controlled studies are needed to evaluate this promising therapeutic approach and confirm its efficacy.
